Prof. Day is the Group Leader of the Sid Faithfull Brain Cancer Laboratory and an internationally recognised expert in brain cancer. He is a Co-Director of the Children’s Brain Cancer Centre, a national initiative to improve outcomes for children with brain cancer. The focus of his laboratory’s research is to better understand the molecular mechanisms which drive the most common and aggressive forms of adult and paediatric brain cancers.
Among Prof. Day’s achievements is the characterisation of the receptor EphA3 as a therapeutic target in GBM. This research has led to clinical testing of a novel EphA3 targeting therapeutic antibody in patients with recurrent brain cancer; and the development of a brain tumour and cell culture bank at QIMR Berghofer, which has collected >350 tumour specimens to-date.
Prof. Day has more than 1500 career citations and has published over 50 scientific articles directly relating to understanding the biology of brain cancer and defining new therapies to treat these aggressive diseases.